GSK 2636771

Drug Profile

GSK 2636771

Alternative Names: GSK2636771

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Institute of Cancer Research; Yonsei University Health System
  • Class Antineoplastics; Benzimidazoles
  • Mechanism of Action Phosphatidylinositol 3 kinase beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I/II Gastric cancer; Malignant melanoma; Solid tumours

Most Recent Events

  • 24 Nov 2017 Phase-II clinical trials in Prostate cancer (Combination therapy, Late-stage disease, Metastatic disease) in United Kingdom (PO)
  • 24 Nov 2017 Phase-II clinical trials in Prostate cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO)
  • 22 Nov 2017 Phase-I clinical trials in Prostate cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top